News

Yahoo Finance1y
ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors
Based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s ENHERTU that showed clinically meaningful responses across a broad range of tumors ENHERTU now has five approved indications ...
Reuters3y
AstraZeneca boosts oncology credentials with breast cancer trial success
Enhertu prolongs survival and slows tumour growth in trial First trial result in new low-HER2 breast cancer category Enhertu is antibody drug combined with cytotoxic chemical Astra to discuss ...
Yahoo Finance2mon
ENHERTU® Approved in the EU as First HER2 Directed Therapy for Patients with HR Positive, HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine ...
Based on DESTINY-Breast06 phase 3 trial results which showed ENHERTU demonstrated superiority versus chemotherapy with a median progression-free survival of more than one year Approval brings ...